A Randomized, Double Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events in Subjects at High Risk for Acute Kidney Injury Following Cardiac Surgery